Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive ‘mid-size’ Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Exp Clin Cancer Res
Main Authors: Allegretti, Matteo, Fabi, Alessandra, Buglioni, Simonetta, Martayan, Aline, Conti, Laura, Pescarmona, Edoardo, Ciliberto, Gennaro, Giacomini, Patrizio
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2018
Fag:
Commentary
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838869/
https://ncbi.nlm.nih.gov/pubmed/29506529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0702-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker